Medtronic announced that the United States FDA has approved the Symplicity Spyral renal denervation system, also known as the Symplicity blood pressure procedure, for the treatment of hypertension. With this approval, Medtronic will immediately begin commercialization.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MDT:
- Acutus Medical to reduce workforce by 65% in corporate restructuring
- Medtronic call volume above normal and directionally bullish
- Medtronic announces four-year results from Evolut Low Risk Trial
- Medtronic receives FDA approval for extravascular defibrillator
- Medtronic price target lowered to $90 from $100 at Mizuho